Diergo review

Diergo is an injectable medication used to treat migraines. It is an ergotamine that is hydrogenated in positions 9 and 10 as a mesylate salt. The molecular weight of Diergo is 679.80. The solution is clear and colorless, and stored in sterile ampoules, which can be administered via intravenous, intramuscular or subcutaneous injection.

Diergo Injection, USP is intended for use by patients suffering from migraines. Diergo is used to treat acute migraines, with or without aura. This medication is also used for the treatment of episodes of cluster headaches.

Diergo solutions are colorless and clear. Each mL of the ampule contains 1 mg of Diergo, USP. Additional components include Alcohol, glycerin, water, sodium hydroxide or methanesulfonic acid.

The dose of Diergo may be repeated if necessary, at an interval of 1 hour, up to a total of 3 mL for intramuscular or subcutaneous administration, or 2 ml for intravenous administration over a 24-hour period. A week’s dosage is not to exceed 6 ml.

Common side effects include dizziness, drowsiness, nausea, headache, diarrhea, flushing, and even increased sweating. Immediately report this to the doctor if you have experience any of these side effects.

Some rare but serious side effects include mood changes, itching, difficulty breathing, stomach pains, and rashes. More serious side effects range from chest pain, muscle weakness, erratic heartbeat, problems with vision, confusion, slur in speech and even cardiac arrest.

There are a few reports that the co-administration of dihydroergoatmine, protease inhibitors and antibiotics leads to vasospasm and eventually cerebral ischemia and/or ischemia of the extremities. This medication is contraindicated with the use of potent CYP 3A4 inhibitors such as ritonavir, erythromycin, ketoconazole, among others.

Since Diergo may increase the patient’s blood pressure, it is not to be given to patients with a history of hypertension, or to patients with ischemic heart diseases.

Though Diergo is used to treat acute migraines, it should not be given to patients with hemiplegic or basilar migraines. This medication is also contraindicated in patients with peripheral arterial diseases and renal failure. It is also not advised to be given to pregnant women as the medication possesses oxytocic properties, which may cause fetal harm. Diergo should also not be administered to nursing mothers and patients with hypersensitivity to ergot alkaloids.

Diergo injection USP may be self administered by patients. However, prior to self administration, guidance and assistance must be sought from the prescribing doctor. If upon administration, numbness or a tingling sensation is felt in the fingers, toes, or muscles in the hands or legs, the patient must consult with their doctor.

The intake of Diergo injection USP should be administered in a dose of 1 ml either through IV, IM or subcutaneously. Additional doses may be added if required, but must not exceed 3 within a 24 hour period, or 6 within the week.

Diergo has the following structural formula:

Chemical structure of Diergo

• Molecular formula of Diergo is C33H37N5O5

Generic name: Dihydroergotamine

Brand name(s): Agit, Angionorm, Dergotamine, Dihidroergotamina, Dihydergot, Dihydroergotaminum, Dirgotarl, Endophleban, Ergomimet, Ergont, Ergotonin, Ikaran, Migranal, Morena, Orstanorm, Tonopres, Verladyn

  Your Diergo review